Phase II Trial Assessing the Repeatability and Tumor Uptake of [⁶⁸Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma.

ABSTRACT: Human epidermal growth factor receptor 2 (HER2) status is used for decision-making in breast carcinoma treatment. The status is obtained through immunohistochemistry or in situ hybridization. These two methods have the disadvantage of necessitating tissue sampling, which is prone to error due to tumor heterogeneity or interobserver variability. Whole-body imaging might be a solution to map HER2 expression throughout the body. Methods: Twenty patients with locally advanced or metastatic breast carcinoma (5 HER2-positive and 15 HER2-negative patients) were included in this phase II trial to assess the repeatability of uptake quantification and the extended safety of the [⁶⁸Ga]Ga-NOTA-anti-HER2 single-domain antibody (sdAb). The tracer was injected, followed by a PET/CT scan

SUBMITTER: Gondry O 

PROVIDER: S-EPMC10858381 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature